AI Article Synopsis
- * Eighty-one patients with type II and III ankle sprains participated, being split into a control group (treatment only) and a study group (treatment plus venotonic). Measurements of ankle swelling and pain were taken at multiple points.
- * The results showed no significant differences in swelling or pain levels between the two groups, indicating that venotonic drugs do not enhance recovery following moderate to severe ankle sprains.
Article Abstract
Objective: Lower leg oedema after trauma may cause various degrees of pain, disability and delay in patient recovery. In this prospective randomized study, we hypothesized that venotonic drugs had no effect in clinical outcome of patients with ankle sprain.
Patients And Methods: Eighty-one patients with type II and III ankle sprain were screened and randomly assigned for receiving standard conservative treatment alone (control group, 39 patients) or with oral intake of a venotonic drug (micronized purified flavonoid fraction, Daflon 1,000 mg × 3) for 20 days (study group, 42 patients). Measurement of the circumference of ankle region in two different locations and assessment of pain intensity with the Visual Analogue Score were performed at the time of patients' admission and during the 7th and 20th posttraumatic day.
Results: Patients demographics were comparable in both groups. There were no significant differences between the two groups regarding the values of perimeter of ankle joint or pain intensity at all the examined time points.
Conclusions: Venotonic drugs seem not to decrease the posttraumatic oedema or pain in patients who suffer from moderate or severe ankle sprain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00402-011-1266-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescription versus over-the-counter venotonics: HPLC-DAD and static digestive model simulation comparison.
Int Angiol
October 2024
Transplantation Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Background: Venotonics are a class of therapeutically active molecules that have vaso-protective effects. They are used to alleviate venous diseases and disorders, particularly venous insufficiency. We compared the composition of prescription versus over-the-counter (OTC) venotonics using high-performance liquid chromatography with UV detection (HPLC-DAD) and simulating their digestion using a static digestive model.
View Article and Find Full Text PDFNew Perspectives on Micronised Purified Flavonoid Fraction in Chronic Venous Disease: From Microvalves to Clinical Effectiveness.
Adv Ther
October 2022
Department of Surgery, Vascular Screening and Diagnostic Centre, University of Nicosia Medical School, Engomi, 2 Kyriacou Matsi Street, Ayios Dhometios, 2368, Nicosia, Cyprus.
The importance of chronic venous disease (CVD), as a cause of reduced quality of life and increased costs to healthcare systems, is expected to rise in parallel with population aging and the increasing prevalence of obesity. Venoactive drugs (VADs) are frequently used to treat the symptoms and signs of CVD. The most commonly used and widely studied VAD, micronised purified flavonoid fraction (MPFF), is effective at all stages of CVD, and has been shown to significantly reduce leg pain, leg heaviness and swelling, as well as ankle oedema and functional discomfort, in clinical trials.
View Article and Find Full Text PDFGinkgo biloba, troxerutin and heptaminol chlorhydrate combined treatment for the management of venous insufficiency and hemorrhoidal crises.
Eur Rev Med Pharmacol Sci
July 2022
Department of Vascular Surgery, Tbilisi State Medical University, Tbilisi, Georgia.
Objective: Ginkor Fort® (Tonipharm, Recordati Group; GB-T-H combined treatment) comprises ginkgo biloba extract, troxerutin and heptaminol chlorhydrate. It is a venotonic and vasculoprotective agent that strengthens veins, increases vessel resistance, and reduces permeability. Thanks to these synergistic actions, it is indicated for the treatment of signs and symptoms of venous insufficiency (VI) and signs related to the hemorrhoidal crisis.
View Article and Find Full Text PDFLymphotonic activity of Ruscus extract, hesperidin methyl chalcone and vitamin C in human lymphatic smooth muscle cells.
Microvasc Res
January 2022
Bioalternatives, 1 bis rue des plantes, 86160 Gençay, France.
Objective: Besides actions including their venotonic, anti-inflammatory, and anti-oxidant effects, venoactive drugs are expected to act on edema via their action on lymphatics. The objective of this study was to evaluate the effect of the combination of Ruscus, hesperidin methyl chalcone and Vitamin C (Ruscus/HMC/Vit C) on intracellular calcium mobilization and contraction of human lymphatic smooth muscle cells (LSMCs) to better characterize the mechanism of its lymphotonic activity.
Methods: Calcium mobilization was evidenced by videomicroscopy analysis of the fluorescence emitted by a specific Ca sensitive dye and measured after injection of Ruscus/HMC/Vit C at 0.
[Case of effective endovascular treatment of venous gangrene].
Angiol Sosud Khir
September 2021
Department of Endovascular Surgery, Orel Regional Clinical Hospital, Orel, Russia.
Presented in this article is a clinical case report regarding treatment of a patient with deep vein thrombosis complicated by venous gangrene having developed 10 days after the onset of the disease. Conservative therapy (infusion of colloids and crystalloids, anticoagulants, agents improving microcirculation, venotonics, nonsteroidal anti-inflammatory drugs, elevated position of the limb) made it possible to stabilize the patient's condition, but not improving haemodynamics of the affected limb. A decision was made to use endovascular techniques.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!